Technology

Disrupting the Cell Performance Status Quo

Capture & Convert Reactive Oxygen Species(ROS): A Dual Approach for Actively Controlling Oxidative Stress

Xheme’s technologies were validated by external agencies and academic partners to significantly increasing the VCD of a variety of types of CHO cells and IgG yield, VCD of HEK293 cells and Jurkat cells, increasing the shelf life, functional health of human blood and reduction of lipid per oxidation and improved nutritional quality of human milk. 

A Robust & Expanding Intellectual Property Portfolio

Currently, Xheme has three issued patents and seven pending patent applications which can be broadly divided into the following categories.

  • Bioprocessing
  • Stored Blood and Blood Components
  • Polymers, Resins, Plastics, and Packaging materials
  • Paints and Coating Formulations
  • Compositional Matter-core Technology
  • Additive Technology to Stop Free Radical Chain Propagation